TDP-43, formally TAR DNA-binding protein 43, is a 414-amino-acid protein that in healthy cells lives mainly in the nucleus, binding thousands of RNA transcripts and steering their splicing, stability, export and translation. In disease it defects: in roughly 97 percent of ALS cases and about half of frontotemporal dementia cases, TDP-43 abandons the nucleus, becomes hyperphosphorylated and ubiquitinated, and precipitates into cytoplasmic inclusions that form the pathological signature of the illness. Under stress, the protein also shuttles into cytoplasmic stress granules, one reason scientists have long suspected a tie between TDP-43 and granule pathology. Rare inherited point mutations in the TDP-43 gene cause ALS outright. One of them, G376D — a glycine-to-aspartic-acid substitution at position 376 in the protein’s glycine-rich C-terminal region — drives cytoplasmic mislocalization and has been linked to mitochondrial and lysosomal malfunctions. What has remained unclear is how a nuclear RNA-binding protein could sabotage lysosomal biology at all, because TDP-43 was not known to hold a direct foothold in the trafficking system that delivers autophagosomes to their destination. The new study supplies that foothold.

The team attacked the problem from the autophagy side. They silenced TDP-43 in cultured cells and surveyed what happened to known components of the degradative machinery. One protein stood out immediately: RILP, the Rab-interacting lysosomal protein, a well-characterized effector of RAB7A. When TDP-43 disappeared, RILP abundance fell sharply — not a minor fluctuation, but a drop deep enough to leave cells short of the adaptor they need to handle late endosomes and autophagosomes. The same collapse followed expression of the ALS-causative G376D mutant, and with it the cells’ autophagic flux — the complete, quantifiable throughput of the autophagy pathway, from autophagosome formation to lysosomal degradation — was compromised. A stalled flux is more dangerous than it sounds: autophagosomes keep forming and capturing cargo, but the cargo is never digested, so the cell fills with undegraded protein aggregates and damaged organelles. Notably, RILP messenger RNA levels were largely preserved, hinting that TDP-43 was acting not on the RILP gene’s transcript but on a later stage of protein production.

RILP’s job description explains why losing it is catastrophic. RAB7A is a molecular switch anchored on late endosomes and autophagosomes, and RILP is one of its principal effectors: through RILP, RAB7A recruits the dynein–dynactin motor complex that hauls vesicles retrograde along microtubules and helps position them for fusion with lysosomes. Without sufficient RILP, vesicles that should converge on lysosomes idle in the cytoplasm, loaded but undelivered. The damage radiates into a second ALS-relevant system: stress granules, the transient, membraneless assemblies of stalled messenger ribonucleoprotein particles that form when cells are under stress and that must either dissolve or be cleared once the crisis passes. Granules that linger become potential breeding grounds for the pathological aggregates seen in ALS. In TDP-43-compromised cells, stress granule markers piled up — consistent with a clearance system too weakened to keep granule turnover on schedule, and with the homeostatic balance between granule formation and dissolution tipping toward persistence.

The decisive test was a rescue. When the researchers forced extra RILP into TDP-43-depleted cells, or into cells expressing the G376D mutant, autophagic flux rebounded and stress granule marker levels dropped. The result established RILP as an effector acting downstream of TDP-43 in this pathway and demonstrated that RILP can overcome TDP-43 malfunctioning rather than merely suffering from it. The rescue also carried an immediate therapeutic implication: if TDP-43 toxicity flows in part through RILP depletion, then restoring RILP — whether by delivering the gene, stabilizing its synthesis, or manipulating the pathways that control it — might counteract several damaging consequences of the mutant protein at once instead of attacking each symptom separately. For a disease in which hundreds of downstream failures have been catalogued, a single upstream node with pleiotropic rescue effects is precisely the kind of target that drug developers prize.

How TDP-43 governs RILP emerged from polysome profiling, a technique that separates messenger RNAs by centrifugation according to how many ribosomes are riding on them; ribosome-heavy fractions sediment farther, marking transcripts that are being translated efficiently. In TDP-43-depleted cells, RILP mRNA shifted away from these heavy polysomes into lighter fractions containing few ribosomes per transcript. Less RILP protein was therefore produced from the same amount of messenger RNA — a translational defect, not a transcriptional one. The finding adds an unexpected item to TDP-43’s already crowded portfolio: beyond regulating RNA splicing, stability and microRNA processing, the protein evidently safeguards the translational efficiency of a key lysosomal-trafficking gene. Because TDP-43 binds thousands of transcripts, the authors suggest that other effectors of cellular logistics may likewise depend on its translational stewardship, with RILP simply the first to be caught in the act.

That mechanism opened a strikingly simple experimental door. The team found that L-leucine — an essential amino acid best known for activating the nutrient-sensing kinase complex mTORC1 — restored RILP levels both in TDP-43-depleted cells and in cells expressing the G376D mutant. The rescue vanished when mTOR signaling was inhibited or when protein synthesis was blocked, confirming that leucine acts by re-engaging mTOR-dependent translation rather than through any unrelated route. In effect, a nutrient signal could partially substitute for the translational control that TDP-43 normally provides. The authors frame this as mechanism, not medicine: the experiments were conducted in cell and neuron models, and leucine supplementation is not being proposed as an ALS therapy. Even so, the result sketches a pharmacological strategy — biasing the translational apparatus toward RILP production — that could in principle be pursued with molecules acting on the same pathway more precisely and safely.

The strongest evidence came from human motor neurons. Working with the Cellular Reprogramming Unit of the Fondazione IRCCS Casa Sollievo della Sofferenza, the team reprogrammed cells from patients carrying the G376D mutation into induced pluripotent stem cells and then differentiated them into motor neurons — precisely the cell type that degenerates in ALS. In these patient-derived neurons, RILP was again downregulated and autophagic flux again defective, faithfully reproducing the defects seen in simpler models. The rescue held there too: boosting RILP improved autophagy and increased cell viability in the mutant motor neurons. Behind the data stands a human story. The paper is dedicated to the memory of Professor Vincenzo La Bella, who directed the ALS Clinical Research Center in Palermo, supplied the patient cells and championed the project before his premature death. The samples were collected under approved ethical protocols with informed consent, in accordance with the Declaration of Helsinki.

The final piece was physical. Co-immunoprecipitation experiments showed that TDP-43 sits in molecular complexes containing both RILP and RAB7A, but only the RILP contact is direct — RAB7A is drawn in through its effector. Mapping the interface revealed that binding occurs between RILP’s C-terminal region and amino acids 320 to 346 of TDP-43, a stretch inside TDP-43’s C-terminal low-complexity domain, the same neighborhood where pathogenic mutations, including G376D, cluster. The surprise came when the mutant was tested: TDP-43G376D bound RILP more strongly than the wild-type protein. A stickier grip sounds benign, but its consequences were destructive. Cells expressing the mutant showed a weakened interaction between RILP and RAB7A, implying that the pathogenic protein sequesters RILP into complexes where it can no longer serve RAB7A. The mutation thus attacks the axis on two fronts simultaneously — it binds RILP too tightly and misdirects it, and it suppresses RILP synthesis through translational repression.

Taken together, the study defines a TDP-43–RILP–RAB7A axis in which an RNA-binding protein, a lysosomal adaptor and a Rab GTPase operate as one functional circuit — and shows how a single ALS mutation can cut that circuit at multiple points at once. Such convergence may explain why mitochondrial, lysosomal and stress granule defects so often travel together in ALS tissue, and why models that target any single process have struggled to capture the full disease. It also marks where future interventions could aim: raising RILP abundance, protecting the RILP–RAB7A interface, or reactivating RILP translation through mTOR-sensitive pathways. The authors caution that the work remains preclinical — rescue experiments in cultured cells and patient-derived neurons do not yet constitute a therapy, and delivering protein-restoring treatments to spinal motor neurons remains one of neuroscience’s hardest delivery problems. But the conceptual shift is substantial. After two decades centered on RNA misprocessing and protein aggregation, ALS biology now has a third pillar — TDP-43’s guardianship of the cell’s autophagy infrastructure — and a new, testable target.

The study, recently published in Acta Neuropathologica Communications, goes beyond previous understandings of autophagy in ALS by focusing specifically on CMA, a selective mechanism by which cells degrade aberrant or damaged proteins. Unlike macroautophagy, which broadly targets cellular debris, CMA identifies and degrades specific protein cargos, a function essential to maintaining neuronal homeostasis. In ALS, where toxic aggregates of the RNA-binding protein TDP-43 accumulate abnormally in motor neurons, the failure of such precision clearance mechanisms could be a driver of cellular degeneration.

To delve into these molecular intricacies, researchers obtained post-mortem spinal cord tissues from ALS patients enrolled in clinical trials and from age-matched healthy donors. Employing advanced immunohistochemistry and immunofluorescence techniques, they quantified levels of LAMP2A, a lysosomal membrane receptor pivotal for substrate translocation in CMA. Strikingly, motor neurons from ALS patients exhibited a pronounced reduction in LAMP2A expression and activity compared to controls, pointing to a compromised CMA pathway as a consistent hallmark in the diseased state.

ALS predominantly affects motor neurons, specialized nerve cells responsible for initiating muscle contractions. In the majority of ALS cases, these neurons harbor cytoplasmic aggregates of TDP-43, a protein normally residing in the nucleus and involved in RNA metabolism. The aberrant cytoplasmic localization of TDP-43 is toxic, disrupting cellular function and viability. The researchers propose that a decline in CMA preferentially impairs the degradation of such proteins, facilitating their pathological accumulation. This observation challenges prior assumptions that generalized autophagy declines were solely responsible, highlighting CMA’s unique and indispensable role.

Professor Salvador Martínez, the laboratory director overseeing this research, emphasized that restoring CMA function may be pivotal for motor neuron survival. “Motor neurons require exceptionally high CMA activity to maintain proteostasis. When this system falters, as observed in ALS, these neurons become especially vulnerable, leading to the progressive neurodegeneration characteristic of the disease,” he explained. This insight underscores the therapeutic potential of pharmacologically or genetically modulating CMA to augment its protein-clearance capacity.

One of the most compelling aspects of this investigation is the direct demonstration of CMA dysfunction in human neuronal tissue, a feat rarely achievable in animal models. This human-centric approach affirms the biological relevance of CMA alterations and enhances translational prospects. The detailed cellular analyses reveal that the malfunction is not an incidental side effect but a targeted failure of protein clearance pathways specific to motor neuron populations impacted by ALS.

The scientific team’s multidisciplinary collaboration included experts from the UMH Sports Research Centre and the Pascual Parrilla Murcia Institute for Biosanitary Research, reflecting the integrated efforts required to tackle a disease of such complexity. They point out that this work was only feasible thanks to the invaluable donations of neural tissue by ALS patients and their families. Such altruistic contributions provide irreplaceable biological material essential for unraveling ALS mechanisms and testing novel hypotheses.

Mechanistically, chaperone-mediated autophagy involves the recognition of substrate proteins by cytosolic chaperones, which then transport these targets to lysosomal membranes bearing LAMP2A receptors. Following binding, substrates translocate into the lysosome for degradation, thus preventing toxic protein build-up. The discovery that LAMP2A expression is diminished in ALS motor neurons suggests that this critical gateway is impaired, obstructing the selective removal of pathological proteins like TDP-43 and potentially amplifying neurotoxicity.

This study’s findings pave the way for exploring CMA-enhancing therapies that could restore cellular balance in ALS-affected neurons. By developing small-molecule activators or gene therapies aimed at increasing LAMP2A levels or stabilizing chaperone function, researchers aim to reverse toxic protein accumulation. Although in the early stages, such strategies could transform the current landscape of ALS treatment, which remains largely supportive without disease-modifying options.

The researchers also underscore the necessity of further investigations to elucidate how CMA dysfunction interacts with other cellular degradation pathways and contributes to the complex ALS pathology. Synergistic therapeutic strategies combining CMA enhancement with modulation of other proteostatic mechanisms may hold the key to achieving meaningful clinical benefits. This integrative view deepens understanding of motor neuron biology under stress and neurodegenerative demands.

Funding for this pivotal work came from several prestigious sources, including the Spanish State Research Agency’s Severo Ochoa Excellence Programme, the Ministry of Science, Innovation and Universities, the Generalitat Valenciana’s Prometeo Programme, and the Instituto de Salud Carlos III’s Advanced Therapies Network (TERAV). Additionally, support from the Next Generation EU initiative and UMH’s Gregoria Ramos Gil Chair on ALS was instrumental in facilitating comprehensive research efforts.

In conclusion, this landmark study reveals that chaperone-mediated autophagy is critically impaired in spinal motor neurons affected by ALS, contributing to the accumulation of neurotoxic TDP-43 aggregates. This deficiency emerges as a compelling molecular target to develop therapeutic approaches capable of preserving motor neuron integrity and delaying disease progression. As scientists decode the complex interplay of cellular clearance systems, new hope arises for patients facing the relentless challenges of ALS.

Subject of Research: Human tissue samples
Article Title: Chaperone mediated autophagy is deficient in spinal motoneurons of ALS patients with TDP-43 proteinopathy
News Publication Date: 4-Feb-2026
Web References: http://dx.doi.org/10.1186/s40478-026-02238-6
Image Credits: Instituto de Neurociencias UMH CSIC
Keywords: Amyotrophic lateral sclerosis, ALS, motor neurons, TDP-43, chaperone-mediated autophagy, CMA, protein aggregation, neurodegeneration, LAMP2A, autophagy regulation, neurobiology

The integrated stress response is a fundamental cellular mechanism tasked with maintaining proteostasis under a variety of stress conditions, including viral infections, nutrient deprivation, and protein misfolding. Central to the ISR’s regulation is the eukaryotic initiation factor 2B (eIF2B), a guanine nucleotide exchange factor critical for the initiation of mRNA translation. In numerous neurodegenerative diseases, notably ALS, dysfunction of eIF2B leads to impaired protein synthesis and exacerbated cellular stress, culminating in neuronal death. The newly introduced compound, DNL343, specifically targets and activates the eIF2B complex, thereby potentially restoring translational capacity and mitigating downstream pathological cascades.

The research encompasses an intricate series of preclinical experiments using cellular and animal models that recapitulate TDP-43 pathology, a hallmark of ALS and other neurodegenerative disorders. TDP-43, a DNA/RNA-binding protein, is notorious for its abnormal cytoplasmic aggregation that disrupts normal RNA processing and neuronal function. Intriguingly, the application of DNL343 in these models demonstrated a noteworthy attenuation in pathological TDP-43 aggregates. This beneficial effect coincided with normalization of ISR markers and improvement in behavioral phenotypes, providing tangible proof of concept for eIF2B activation as a therapeutic modality.

Beyond the molecular and animal studies, the investigation further extends to a tightly controlled randomized clinical trial involving individuals diagnosed with ALS. The trial’s design underscored rigorous evaluation of safety, pharmacodynamics, and preliminary efficacy of DNL343. Remarkably, patients treated with the compound displayed modulated ISR signaling, affirming the compound’s activity in a human biological context. Although longer term studies are required to elucidate clinical outcomes fully, these findings herald a promising avenue for the modulation of stress responses as a disease-modifying strategy.

A substantial hurdle in the development of ALS therapies has been the heterogeneity of the disease and complexity of underlying pathogenic mechanisms. The integrated stress response, however, represents a convergent pathway implicated across diverse neurodegenerative conditions, making it an attractive target. By directly enhancing eIF2B activity, DNL343 sidesteps some of the pitfalls associated with upstream ISR inhibition, which can lead to undesirable side effects. This nuanced approach allows for a carefully balanced recalibration of protein synthesis without compromising the protective adaptive stress responses necessary for cell survival.

Crucially, the study’s underlying methodology involved the use of cutting-edge biochemical assays to discern the binding dynamics of DNL343 with the eIF2B complex. These analyses revealed that DNL343 stabilizes eIF2B’s active conformation, thereby enhancing its guanine nucleotide exchange function. Such mechanistic insights afford researchers the opportunity to rationally optimize the compound’s efficacy and specificity, setting a precedent for subsequent drug development in this realm.

In the broader context of therapeutic interventions for neurodegenerative disorders, DNL343’s mode of action aligns with a growing body of evidence emphasizing the restoration of proteostasis as a pivotal strategy. Unlike approaches that merely target symptomatic relief or downstream effects, these findings spotlight a pathway that addresses fundamental cellular dysfunction. This molecular focus could recalibrate how the scientific community conceptualizes disease modification, potentially translating into broader applications beyond ALS.

The trial involved extensive biomarker analyses, in which researchers tracked markers indicative of ISR activity, TDP-43 pathology, and neuronal health. These biomarkers provided quantifiable metrics to validate the biological impact of DNL343 administration. The data suggest that modulation of eIF2B activity yields favorable shifts in these crucial parameters, supporting the feasibility of ISR-targeted therapies in a clinical setting.

One of the most compelling aspects of the research lies in its multidisciplinary approach, integrating molecular biology, pharmacology, and clinical sciences. Such a comprehensive strategy has proven essential in unraveling the complexities inherent in neurodegeneration. Importantly, the transition from promising preclinical results to human trials exemplifies a translational milestone, bringing the potential of eIF2B activation therapies closer to real-world application.

While the path forward necessitates expanded trials to establish long-term safety and efficacy comprehensively, the foundational work presented by Flores and colleagues charts a new map for therapeutic exploration. It invites a paradigm shift that may spur the development of analogs or combinatorial regimens targeting the ISR pathway in conjunction with other modalities, amplifying therapeutic potential.

Furthermore, the study’s findings may reverberate beyond the sphere of ALS and TDP-43-linked diseases. Given that ISR dysregulation is implicated in a spectrum of pathological contexts—ranging from Alzheimer’s disease to Parkinsonian syndromes—the implication of eIF2B activators like DNL343 could extend to these disorders as well. Future investigations are poised to explore these exciting possibilities, potentially ushering in a new era of neuroprotective treatments.

A critical aspect of advancing such therapeutics involves navigating the delicate balance between modulating stress responses adequately without impairing the cell’s inherent capacity to manage acute insults. The elegance of DNL343’s mechanism lies in its capacity to fine-tune this balance, thereby restoring homeostasis rather than overwhelming cellular systems. This therapeutic sophistication sets a new standard for molecular design in neurodegenerative medicine.

With neurodegenerative diseases exerting an ever-increasing toll on global health, breakthroughs like this inject a much-needed infusion of optimism into the field. The multifaceted approach adopted by this research team exemplifies how integrated molecular insights coupled with clinical validation can accelerate the pace of discovering viable interventions. As such, DNL343 stands as a beacon of hope for millions affected by ALS and potentially other related ailments.

In conclusion, the investigation into eIF2B activation via DNL343 represents a landmark achievement that merges molecular innovation with clinical relevance. By successfully modulating the integrated stress response and ameliorating TDP-43 pathology in preclinical models and human subjects, this work elevates the discourse on neurodegenerative disease treatment from symptomatic management to targeted molecular correction. The implications of such work resonate deeply within the scientific community and among patients eager for transformative therapies.

As research continues to build on this foundation, the precise characterization of eIF2B activators’ role in neuronal resilience will be critical. The promising data thus far encourage sustained investment and collaboration across disciplines to further elucidate mechanisms, optimize drug formulations, and expand clinical assessment. The ultimate goal remains to translate these molecular advancements into durable, meaningful clinical benefits.

The journey of DNL343 from bench to bedside exemplifies the synergy that innovative biochemistry and clinical inquiry can achieve. In a landscape often marked by incremental progress, such breakthroughs ignite a renewed sense of purpose and potential. It is a vivid reminder that unlocking cellular stress pathways may hold the key to tackling some of the most intractable neurodegenerative challenges facing humanity today.

Subject of Research: Modulation of the integrated stress response in neurodegenerative disease, specifically targeting eIF2B activation in TDP-43 pathology and ALS.

Article Title: Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.

Article References:
Flores, B.N., Yu, S.B., Cohen, I.V. et al. Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial. Nat Commun 16, 7690 (2025). https://doi.org/10.1038/s41467-025-63031-y

Image Credits: AI Generated